Park Systems: Revenue Growth Continues but Margins and Returns Have Slipped as the Multiple Rises

Thesis

The data supports a picture of a company that has grown revenue every year shown, from ₩85.3B in 2021 to ₩205.6B in 2025. Profit has not kept pace recently. The trailing operating margin of 12.0% (to H1 2026) compares with 20.5% in 2025 and 22.0% in 2024, and trailing ROE of 8.8% compares with 16.7% in 2025.

The share price has risen 18.3% over three months and 12.8% over one year, and sits below the 52-week high of ₩350,500 and well above the low of ₩205,000. The valuation now reflects high expectations relative to trailing earnings. The data does not include guidance, order backlog or segment detail, so the reasons for the margin change cannot be established here. Investor flow, foreign ownership and short balance data are not available.

Business overview

Park Systems is listed on KOSDAQ in the medical and precision devices sector. It was founded on 1997-04-07 and listed on 2015-12-17, with 6,989,977 shares listed. The CEO is listed as 박상일. Market cap is about ₩2.1T and enterprise value about ₩2.0T. Revenue rose from ₩85.3B in 2021 to ₩124.5B in 2022, ₩144.8B in 2023, ₩175.1B in 2024 and ₩205.6B in 2025. Growth rates were 46.1%, 16.3%, 20.9% and 17.5% over 2022 to 2025. The data gives no product or customer breakdown.

Financial analysis

All figures come from filed financial statements (DART), consolidated where available.

For 2025, revenue was ₩205.6B (up 17.5%), operating income ₩42.2B (20.5% margin) and net income ₩34.5B. In 2024, operating income was ₩38.5B and net income ₩42.8B, which was above operating income. In 2023, operating income was ₩27.6B and net income ₩24.6B. Operating margin ranged between 19.0% and 26.2% for 2022 to 2025.

Trailing twelve months to H1 2026: revenue ₩194.8B, operating income ₩23.4B (12.0% margin), net income ₩23.2B (11.9% margin). That revenue figure is below 2025 full-year revenue. ROE is 8.8%, versus 26.7% in 2022 and 25.8% in 2024.

Balance sheet: liabilities to equity of 39.3% and cash of ₩104.5B. Borrowings are not available. Trailing free cash flow is negative at -₩72.3B. Filings in May 2026 show a bond with warrants issue decision and a debt security recognized as capital, but amounts are not in the data.

Valuation

On trailing figures the P/E is 90.6, P/B 6.2 and P/S 10.8. Dividend yield is 0.2%. EV/EBITDA is not available. At year-end 2025 the P/E was 42.4 and P/B 6.5, so the P/E is now roughly double that level while P/B is slightly lower. Earlier year-end multiples are not available.

Peers with data: TSE has a P/E of 32.6 and P/B of 7.2, and Kctech a P/E of 26.9 and P/B of 4.1. Park Systems' P/E is well above both, while its P/B sits between them. Classys, DI and Curiox Biosystems have no multiples in the data.

Our simple five-year DCF model fair value range (bear, base, bull) could not be worked out, in part because trailing free cash flow is negative. No comparison with the ₩300,500 share price is possible.

Catalysts

• Half-year report for June 2026, filed 2026-08-14, showed the trailing margin and ROE levels now reflected in the multiples.
• Several investor relations events (2026-05-19, 2026-08-18, 2026-09-01, 2026-09-04) show active communication with investors.
• Repeated 5%+ holding reports (2026-05-29, 2026-08-07, 2026-09-03) point to changes in major shareholdings, though the details are not in the data.
• The May 2026 bond with warrants decision and June 2026 securities issuance and treasury share disposal reports show capital-raising activity that could affect share count and funding.
• The shares have risen 19.2% in one month, which may attract more attention as they approach the 52-week high.

Risks

• Trailing operating margin of 12.0% is well below the 19.0% to 26.2% seen in 2022 to 2025, and the cause is not given in the data.
• A P/E of 90.6 leaves less room if earnings do not recover, compared with peers at 26.9 and 32.6.
• Trailing free cash flow is negative at -₩72.3B, which may increase reliance on external funding.
• Bond with warrants issuance could dilute existing shareholders if warrants are exercised, and terms are not available.
• Investor flow, foreign ownership, short interest and news data are missing, limiting visibility on market positioning.

Closing view

The data shows a business with a consistent record of revenue growth and a solid balance sheet, with liabilities at 39.3% of equity and ₩104.5B in cash. Against that, trailing margins, ROE and cash flow have weakened, and the share price multiple has risen to 90.6 times trailing earnings, far above the two peers with data. Without a model fair value, guidance or flow data, the evidence is mixed: operating growth is clear, but the current valuation depends on a profit recovery that the filed numbers do not yet show.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

• Investor relations (IR) eventSep 4, 2026
• 5%+ holding reportSep 3, 2026
• Investor relations (IR) eventSep 1, 2026
• Investor relations (IR) eventAug 18, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• 5%+ holding reportAug 7, 2026
• 자기주식처분결과보고서Jun 15, 2026
• 증권발행결과(자율공시)Jun 8, 2026
• 5%+ holding reportMay 29, 2026
• 주요사항보고서(자본으로인정되는채무증권발행결정)May 21, 2026
• Bond with warrants issue decisionMay 21, 2026
• Investor relations (IR) eventMay 19, 2026
• Daily prices up to 2026-10-12
• Financial statements, trailing 12 months as of H1 2026

Report history

1. Oct 13, 2026InitiationStart of coverage (300 largest)Park Systems: Revenue Growth Continues but Margins and Returns Have Slipped as the Multiple Rises